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Abstract
Different types of vaccines have been developed to elicit active immunization to treat various diseases, while suffer
from limitation of efficacy. Herein, a novel immunostimulatory nanocomposite (CpG-Au@HBc VLP) was rationally
designed by self-assembling engineered virus-like particles encapsulating CpG-gold nanoparticle conjugates
through electrostatic interactions. The monodispersed and uniformly sized CpG-Au@HBc VLP showed increased
CD4+, CD8+ T cell numbers and stronger secretion of cytokine interferon-gamma than HBc VLPs adjuvanted with
conventional Freund’s adjuvant. Furthermore, the use of Au nanoparticles also generated enhanced
immunogenicity of CpG and VLPs on both humoral and cellular immune pathways, as followed from increased
expressions of total HBc-specific antibody titer, CD4+ T cells, CD8+ T cells, cytokine interleukin-4, and interferon-
gamma. These findings demonstrated that CpG-Au@HBc VLP nanocomposite could induce robust cellular and
humoral immune response, which could be a potential vaccine for future prophylactic and therapeutic application.
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Background
Vaccines aim at generating the body’s protective and
therapeutic immune responses against many diseases,
such as infectious diseases and cancers [1]. Conventional
vaccines, which are composed of attenuated live and
inactivated vaccines, mostly stimulate humoral immun-
ity, and result in safety concerns [2]. Thus, it is necessary
to develop safety vaccines, which can elicit not only
humoral but also cellular immunity. With the progress
of immunology and molecular biology, a series of bio-
molecules have been utilized as antigens to construct
new vaccine formulations, including recombined virus
or bacteria [3], dendritic cells [4], T cells [5], nucleic
acids [6, 7], and peptides [8]. Among these antigens,
some of the recombined protein, derived from viruses
(such as hepatitis B and C), have been reported to be able
to induce host immune responses [9]. The hepatitis B core
protein (HBc) virus-like particles (VLPs) are self-assembled
by hepatitis B virus core proteins in recombinant expres-
sion systems (Escherichia coli (E. coli)) [10, 11]. HBc VLPs
are hollow and stable without incorporating genetic mate-
rials but still keep similar conformations to the wild virus.
They could be dissociated and re-assembled relying on de-
naturant stock solution such as urea and guanidine by
breaking the disulfide bond among monomers in the VLPs
[12]. Moreover, HBc VLPs have high proper immunogen-
icity on B cell, T cell, and cytotoxic T lymphocyte (CTL)
level [9]. Thus, they are promising candidate vaccine
antigens and nanocarriers to deliver genes, drugs, or
other therapeutics with good biocompatibility and
non-infectiousness. Considering of these features, HBc
VLPs could be employed to construct new types of
vaccine formulation that simultaneously induced robust
humoral and cellular responses [13, 14]. However, the
main concern for using HBc VLPs as vaccines is that it is
insufficient enough to induce immune responses by using
HBc antigens alone.
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Adjuvant is responsible for stronger efficacy of vaccine
and subsequently significant immune responses. Oligo-
deoxynucleotides (ODNs) containing unmethylated CpG
motifs (CpG ODNs) have been utilized as potent adjuvants
with negligible toxicity, due to their wide stimulation to
macrophage cells, dendritic cells, natural killer (NK) cells,
and B cells [15]. CpG ODNs can not only activate innate
and acquired immune responses but also preferentially in-
duce T helper 1(Th1) responses on antigen-specific T cell
responses, which is more preferred for immunization
against many diseases [16, 17]. Nevertheless, some draw-
backs are still needed to conquer. CpG ODNs cannot
penetrate through cell membrane and are easy to be
cleared by nucleases in plasma or cytoplasm [18]. Some
transfection agents have been employed to improve deliv-
ery of CpG ODNs into targeting cells [19, 20], due to their
potential to prolong the tissue retention time of loaded
therapeutics, and to reduce exposure time of CpG ODNs
in systemic circulation. The rapid development of nano-
technology also raises new promises in the generation of
novel adjuvant systems based on nanoparticles. These
nanoparticles are well suited for delivery of immune
therapies and can cause immune responses by themselves
[21–23]. Gold nanoparticles (Au NPs), with excellent bio-
compatibility, easily tuned sizes and modification, have
been extensively applied to antigens and immune adjuvant
delivery [24]. They are able to protect immune therapeutic
molecules like CpG ODNs from degradation. Some kinds
of Au NPs, for example, gold nanorods (Au NRs), were
also found to exhibit adjuvant activities although the de-
tailed mechanisms still need further investigation [25].
Nevertheless, the co-immune effect of the CpG ODNs, Au
NPs, and HBc VLPs still lack of research.
In the present work, we developed CpG-Au@HBc VLPs
as an immunostimulatory nanocomposite in which the
CpG ODNs adjuvant was conjugated with Au NPs and
co-encapsulated by genetically engineered HBc VLPs. The
designed nanocomposite showed the ability to induce
robust specific T cell response and enhanced Th1-type
immune response than HBc VLPs co-immune with con-
ventional adjuvant. It was also revealed that Au NPs could
enhance the immune stimulation of CpG ODNs on both
humoral and cellular immune response. As a result, the
CpG-Au@HBc VLPs might be a potential vaccine for fu-
ture prophylactic and therapeutic application.
Methods
Materials
Chemicals including chloroauric acid trihydrate
(HAuCl4·3H2O), sodium citrate, sodium chloride (NaCl),
potassium chloride (KCl), sodium phosphate dibasic
(Na2HPO4), potassium phosphate monobasic (KH2PO4),
10 % sodium azide (NaN3), Tris(hydroxymethyl)amino-
methane (Tris-HCl), isopropyl-β-D-thiogalactoside (IPTG),
Triton, ammonium sulfate ((NH4)2SO4), sodium dodecyl
sulfate (SDS), glycerol, glycine, and Tween-20, were pur-
chased from Sinopharm Chemical Reagent Co., Ltd
(Shanghai, China). Bovine serum albumin (BSA), Freund’s
adjuvant complete and Freund’s adjuvant incomplete were
purchased from Sigma-Aldrich (Sigma-Aldrich St Louis,
MO, USA). Horseradish peroxidase (HRP) conjugated
anti-mouse antibody, 3, 3′ 5, 5′-tetramethylbenzidine
(TMB), PE/Cy5 anti-mouse CD8a, and FITC-CD4 anti-
mouse CD4 were purchased from Ebioscience Biotechnol-
ogy (USA). High affinity purification purified CpG ODNs
(5′-TCCATGACGTTCCTGACGTT-SH-3′) were synthe-
sized by Sangon Biotech Co., Ltd (Shanghai, China). Unless
otherwise noted, all chemicals were analytical grade and
used without further purification. Milli-Q water (less than
18.2 MΩ cm) was used throughout the whole experiment.
Expression and Purification of Full-Length HBc VLPs
The coding sequence of the full-length HBc antigen
(HBcAg) was amplified from the plasmid pET-43.1a.
Amino acid sequence of the full-length HBcAg was the
same as the published report [11]. The expression and
purification of full-length HBc VLPs were conducted ac-
cording to our previous methods [26]. Briefly, prokary-
otic vector E. coli BL21 (DE3) strain containing the
expression plasmid was cultured and induced to express
HBc VLPs. After the expression, HBc VLPs were sepa-
rated and purified successively (detected by sodium do-
decyl sulfate polyacrylamide gel electrophoresis) by
salting out with saturated ammonium sulfate, DEAE
ion-exchange chromatography, and Sepharose CL 4B
molecular exclusion chromatography. The purified HBc
VLPs were ultrafiltered to reach a final concentration of
2 mg/mL in PBS and stored at −20 °C.
Synthesis of Au NPs
Citrate-stabilized gold nanoparticles with small size were
prepared using a modified seed-mediated method re-
ported by Frens et al. [27]. Briefly, HAuCl4 aqueous so-
lution (250 μL, 100 mM) was added to 100 mL ultrapure
water and heated to boiling, then trisodium citrate solu-
tion (3.5 mL, 1 %, w/v) was added quickly under vigorous
stirring. After reaction for 20 min, the Au solution was
cooled down to room temperature. The as-synthesized Au
NPs were kept at 4 °C.
Functionalization of Au NPs with CpG ODNs
The assembly of Au NPs with CpG ODNs was con-
ducted by using a salt-aging approach as follows. Firstly,
sulfhydryl-modified CpG ODNs (5 μL, 100 μM) and Au
NPs solution (5 mL, 10 nM) were mixed at 16 °C for
12 h. The solution was adjusted to 0.1 % SDS and
10 mM of PBS buffer (pH 7.4). Then the concentration
of NaCl in the solution was slowly increased to 0.1 M in
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a 6-h time window by stepwise addition of 1 M NaCl
aqueous solution. The mixture solution was shaken for
12 h at room temperature to make sure the Au NPs
were fully covered by thiolated CpG ODNs. CpG-Au NP
conjugates were then centrifuged (18,000 rpm, 20 min,
4 °C) and washed with 0.1× PBS buffer for three times
to remove the extra CpG ODNs. The final precipitate
was dissolved in PBS for further use.
To quantify the accurate amount of CpG ODNs bound
to each Au NP, a fluorescence-based method was used
[28]. Briefly, conjugation of 5′-FAM-CpG ODNs with
Au NPs was performed with the same protocol as men-
tioned above. 2-mercaptoethanol (final concentration
12 mM) was then added to the solution and shaken
overnight to replace the binding 5′-FAM-CpG ODNs.
The solutions containing displaced 5′-FAM-CpG ODNs
were separated from the Au NPs by centrifugation. Then
the fluorescence emission intensity of FAM molecules at
520 nm was measured to quantify the concentration of
displaced CpG ODNs. Dividing by the Au NPs concen-
tration obtained from UV-vis spectroscopy measure-
ments [29], the number of CpG ODNs released from
per Au nanoparticle was determined.
Construction of CpG-Au@HBc and CpG@HBc VLPs
The HBc VLPs were firstly dissociated by adding dissociat-
ing buffer (3 M urea, 150 mM NaCl, and 50 mM Tris-
HCl) with a final concentration of 1 mg/mL and incubated
for 3 h at room temperature. Then CpG-Au NP conjugate
solution (2.5 mL, 20 nM) or free CpG ODNs (10 μL,
1 mg/mL) were added and incubated for 30 min under
slight shaking to form CpG-Au@HBc VLPs or CpG@HBc
VLPs, respectively. Finally, samples were dialyzed over-
night against reassembling buffer (10 mM Tris, 150 mM
NaCl, 10 % glycerol, 1 % glycine, pH 8.0) at 4 °C, and de-
tected by agarose gel electrophoresis.
Mice and Immunization
Six-week-old pathogen-free female BALB/c mice were
obtained from Shanghai Laboratory Animal Center of
Chinese Academy of Sciences (China) and kept at the
Animal Center of Xiamen University. All animal experi-
ments were conducted according to the guidelines of the
Institutional Animal Care and Use Committee. The mice
were randomly divided into five groups (six mice per
group). Then the mice were injected intraperitoneally
with following vaccine formulations (0.2 mL) (a) 50 μg
HBc VLPs only, (b) CpG@HBc VLPs: 50 μg HBc VLPs
encapsulated 10 μg CpG ODNs, (c) CpG-Au@HBc
VLPs: 50 μg HBc VLPs encapsulated CpG-Au NP conju-
gates containing 10 μg CpG ODNs, (d) CpG-Au +HBc
VLPs: 50 μg HBc VLPs mixed with CpG-Au NP conju-
gates containing 10 μg CpG ODNs, (e) CFA/IFA +HBc
VLPs: HBc VLPs mixed with Freund’s adjuvant (positive
control): 50 μg HBc VLPs mixed with 50 μg complete
Freund’s adjuvant (CFA) for the first injection, and 50 μg
HBc VLPs mixed with 50 μg incomplete Freund’s adju-
vant (IFA) for the other three injections, and (f ) PBS
(0.01 M, pH = 7.4) as blank control. Mice were immunized
on days 0, 7, 14, and 21, respectively. After immunization
for the 4 weeks, all mice were sacrificed on day 28. The
sera and splenocytes of mice were harvested for further
analysis.
Detection of HBc-Specific IgG Antibody
96-well plates were coated with HBc VLPs in coating
buffer (1 mg/mL in 50 mM sodium carbonate buffer, pH
9.6, 100 μL per well) overnight at 4 °C. Wells were
washed three times with PBS containing 0.05 % Tween-
20 then blocked by 1 % BSA at 37 °C for 1 h. After
washing with PBS, diluted mouse serum samples col-
lected after each immunization were incubated at 37 °C
for 1 h, followed by washing three times, 100 μL of
horseradish peroxidase (HRP)-conjugated anti-mouse
antibody at different dilutions (1:100, 1:1000, and
1:10,000) were added to wells. The plates were incubated
at 37 °C for 1 h and washed again. TMB substrate solu-
tion was added to each well and incubated for 15 min at
37 °C. Then H2SO4 was added to have color reaction.
Finally, the absorbance of samples at 450 nm was mea-
sured with microplate reader.
Detection of CD4+ and CD8+ T Cells in Mice Splenocytes
The splenocytes were separated after mice of all five groups
were euthanized. Then, splenocytes were stained by fluores-
cent antibodies (PE/Cy5 anti-mouse CD8a and FITC anti-
mouse CD4, respectively) on ice for 30 min, and cells were
subsequently washed with ice-cold PBS, containing 0.1 %
NaN3 and 0.5 % BSA. The expression of CD4
+ and CD8+ T
cells were determined by flow cytometry analysis.
Cytokine Test
The level of cytokine interferon-gamma (IFN-γ),
interleukin-2 (IL-2), and interleukin-4 (IL-4) from mice
serum in the presence of the four different vaccine
formulations were analyzed with the cytokine enzyme-
linked immunosorbent assay (ELISA) kits (R&D system,
USA). All operations were performed following the man-
ufacturer’s instructions.
Characterization
Transmission electron microscopy (TEM) images were
obtained by a JEM-1400 (JEOL, Japan) operated at an
accelerating voltage of 100 kV. Protein samples for TEM
analysis were prepared by spreading a drop of the sam-
ple dilute dispersion on carbon film-coated copper grids
followed by staining with 1 % uranyl acetate. Dynamic
light scattering (DLS) and zeta potential distribution
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were measured on a Malvern Zetasizer Nano ZS
(Malvern, UK). UV-vis absorption spectra were acquired
with a DU 800 UV-vis spectrophotometer (Beckman
Coulter, Fullerton, CA). The fluorescence emission spec-
tra were obtained by FluoroMax-4 spectrometer (Jobin
Yvon Horiba, France). Flow cytometry analysis was per-
formed on a Coulter Epics XL flow cytometer (Beckman
Coulter, Fullerton, CA). Optical absorbance measure-
ments in ELISA assays were performed on Bio-Rad
Model 680 microplate reader (Bio-Rad, USA).
Statistics
Data for each experiment were presented as mean values ±
standard deviation (SD). Comparisons between two groups
were performed by two-tailed Student’s t test. p values
below 0.05 were considered as significant and indicated
with * in the figures.
Results and Discussion
Characterization of HBc VLPs
VLPs generated from HBc proteins have been constructed
to inducibly and efficiently express in E. coli system and
purified by salting out, ion-exchange chromatography,
and molecular exclusion chromatography. Sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
result (Fig. 1a) showed the significantly improved purity of
proteins through purification by salting out and chroma-
tography. The monomer molecular weight of full-length
HBc VLPs was measured around ~20.9 kDa. The hydro-
dynamic size of HBc VLPs was ~34 nm by DLS analysis
(Fig. 1b). The protein demonstrated good capability for
self-assembling into icosahedral particles (average size was
30.8 ± 1.3 nm) with empty inner cavity of 20.6 ± 0.7 nm in
diameter according to TEM negative staining investigation
(Fig. 1c). The as-prepared full-length HBc VLPs showed
consistent size and morphology with that reported in pre-
vious studies [13, 30].
Characterization of CpG-Au NP Conjugates
Small-sized Au NPs were prepared according to a modi-
fied seed-mediated method. The TEM image in Fig. 2a
showed the obtained Au NPs were homogeneous and
monodisperse. The average size of Au NPs was measured
at 10.5 ± 1.2 nm. Thiolated CpG ODNs (5′-TCCAT
GACGTTCCTGACGTT-3′-SH), an effective sequence to
stimulate immune responses of mice [31], could be suc-
cessfully modified on Au NPs to form CpG-Au conjuga-
tions through Au–S bond. After CpG ODNs coating, the
hydrodynamic size of Au NPs was increased from 12.4 to
20.5 nm (Fig. 2b), and an absorption peak at 280 nm was
observed (Fig. 2c), corresponding to the characteristic ab-
sorption peak of CpG ODNs. These results demonstrated
that thiolated CpG ODNs have been loaded on the surface
of Au NPs. According to the calculation, for the as-
prepared Au NPs, the surface coverage is ∼31 CpG ODNs
per nanoparticle (Fig. 2d).
Characterization of HBc VLPs Encapsulated CpG-Au NPs
and CpG
To reach an enhanced immunostimulatory effect, we inte-
grated antigen with adjuvant by designing CpG-Au@HBc
VLPs nanocomposites. The HBc VLPs were firstly disas-
sembled after incubation with denaturant stock solution to
expose the arginine-rich blocks of each HBc subunit. The
CpG-Au conjugates were subsequently added and co-
incubated for another 20 min using slight vibrational mo-
tion. The reassembly of CpG-Au core-containing VLPs
were performed by dialysising the dissociated HBc VLPs
subunits against an assembling buffer. The as-prepared
CpG-Au@HBc VLPs were finally purified by centrifugation.
TEM images (Fig. 3a) of CpG-Au@HBc VLPs indicated
that Au nanoparticles with higher contrast were success-
fully enclosed inside the HBc VLPs. Moreover, the obtained
CpG-Au@HBc VLPs showed monodisperse, homogeneous,
and remained typical quasi-spherical as HBc VLPs.
Fig. 1 Physicochemical characterization of purified HBc VLPs. a SDS-PAGE analysis of HBc VLPs in different stages of purification, from left to right:
marker, bacterial liquid, protein separation from salting out, ion-exchange chromatography and molecular exclusion chromatography, marker. b
DLS data of HBc VLPs. c TEM analysis of negatively stained HBc VLPs
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To verify whether the CpG ODNs bound on Au NPs
were essential for encapsulation, control experiments were
also conducted. In the first control, the assembly that was
conducted between naked Au NPs alone was mixed with
HBc VLPs, as shown in Fig. 3b. Lots of empty HBc VLPs
and plain Au NPs were observed in Fig. 3b. Another con-
trol experiment was also conducted, in which CpG ODNs
with the absence of Au NP were incubated with HBc sub-
units. The encapsulation capacity of HBc VLPs with CpG
was evaluated by agarose gel electrophoresis (Fig. 3c). It
was observed that CpG ODNs encapsulated into HBc
VLPs exhibited no mobility in the electromobility shift
assay (lanes 2) while free CpG ODNs (lane 1) moved at its
usual position. The result showed complete retardation of
CpG ODNs through encapsulation, confirming that the
formation of CpG@HBc VLPs was achieved. These results
demonstrated that CpG ODNs played a key role to
the encapsulation. Since the C-terminal sequence of
full-length HBc VLPs contains 42 amino acids (aa
141–183) with four highly positive charged reduplica-
tive arginine-rich blocks [32, 33], which were respon-
sible for encapsulation of nucleic acids. The CpG-Au
NPs were packaged inside the VLPs through binding
to capsid-internal arginine repeats.
Fig. 2 Characterization of Au NPs before and after functionalized with CpG ODNs. a TEM images of the as-synthesized Au NPs; b size distribution;
and c UV-vis spectra of Au NPs and CpG-Au NP nanoconjugates. d The fluorescence spectra of the supernatant before (red line) and after (black line)
displacement by mercaptoethanol (MCE) of the fluorescein-tagged, thiolated CpG ODNs
Fig. 3 Characterization of CpG-Au@HBc VLPs and CpG@HBc VLPs. TEM images of negatively stained samples of HBc VLPs encapsulated a CpG-Au
NPs and b Au NPs. c Agarose gel electrophore analysis of CpG ODN (20 bp) encapsulated into HBc (lane 2), lane 1: control experiment with free
CpG at the same mass, lane M: marker
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Evaluation of Humoral Immune Response in Mice
To further evaluate the immunostimulatory properties of
the CpG-Au@HBc VLPs nanocomposite, both humoral
and cell-mediated immune response were considered.
Intraperitoneal immunisations of BALB/c mice were per-
formed with HBc VLPs, CpG-Au@HBc VLPs, CpG-Au +
HBc VLPs, CpG@HBc VLPs, and HBc VLPs mixed with
conventional Freund’s adjuvants (CFA/IFA +HBc VLPs),
which were widely applied to induce both humoral and
cellular immune response, respectively. Humoral immune
responses were documented on days 7, 14, 21, and 28 by
evaluating the anti-HBc titer in the sera of mice. As shown
in Fig. 4, the significant differences of HBc titer among the
five groups were increased after immunization for 4 weeks.
Moreover, increasing the times of immunization was
efficacious to increasing anti-HBc titer. Single HBc VLPs
induced relatively low HBc-specific IgG antibody (1:4600)
when comparing with the adjuvant immune groups (CpG-
Au@HBc VLPs, CpG-Au +HBc VLPs, CpG@HBc VLPs,
and CFA/IFA +HBc VLPs) after the fourth immunization.
These results revealed the weak ability of HBc to stimulate
strong humoral immune response when immune mice
without any adjuvant. The CpG@HBc VLPs group, CpG-
Au +HBc VLPs group, and CpG-Au@HBc VLPs group
also showed humoral immune stimulation. The titer
induced by CpG-Au@HBc VLPs group has no significant
difference with CpG-Au +HBc VLPs group, while
presented obviously improved antibody response than
CpG@HBc VLPs group. After 4 weeks of immunization,
the anti-HBc response induced by CpG-Au@HBc VLPs
was 1:29,900, exceeding ~2.0 times of that induced by
CpG@HBc VLPs (1:14,600). It is thus suggested that
CpG-Au@HBc VLPs could enhance HBc-specific immune
responses might due to Au NPs enhancing the property of
CpG ODNs to stimulate humoral immune responses.
However, the highest end point dilution titers of anti-HBc
(1:49,500) was induced by CFA/IFA +HBc VLPs. This
may due to the large doses of CFA (50 μg) and IFA
(50 μg) used in mice immunization, which could cause
greater side effects than CpG ODNs.
Detection of CD8+ and CD4+ Cell Responses in
Splenocytes
T cells play key roles in cellular immune response [34].
The T cell response to HBc VLPs was determined using
a number of FACS-based T cell assays to evaluate the in-
duced CD4+ and CD8+ T cells in splenocytes, which
were known as two prime T cell subsets. The CD4+ T
cells are mainly T helper (Th) cells, and their responses
can be divided into two types, T helper 1 (Th1) and T
helper 2 (Th2), based upon cytokine secretion and ef-
fector function [35]. Strong cellular immunity associated
with Th1-type immune response is thought to be essen-
tial for the control of intracellular pathogens. Whereas
strong humoral immunity, which can be initiated and in-
duced by Th2-type immune response, appears to be es-
sential for the control of extracellular pathogens [36]. It
was demonstrated that HBc protein possesses many Th
cell epitopes and CTL epitopes [9]. These epitopes con-
tributed to enhancing the immunogenicity of HBc to ac-
tivate cellular immunity. Flow cytometry analysis in
Fig. 5a indicated that the production of CD4+ T cell sub-
set was significantly higher in mice immunized with
HBc than those immunized with PBS (p < 0.05), suggest-
ing that all of the vaccine formulations (HBc, CpG-
Au@HBc VLPs, CpG-Au +HBc VLPs, CpG@HBc VLPs,
and CFA/IFA +HBc VLPs) could activate CD4+ T cell
subsets. The CD4+ T cell in mice immunized with CpG-
Au@HBc VLPs (26.3 %) was much higher than those im-
munized with CpG@HBc VLPs (22.9 %; p < 0.05) and
CFA/IFA +HBc VLPs (21.5 %; p < 0.05), while has no
significant difference with CpG-Au +HBc VLPs (25.7 %;
p > 0.05). The other T cell subset evaluated here was
CD8+ T cells. The antigen-specific CD8+ T cells are
mainly CTL, which are critical for protecting against
intracellular pathogens. Flow cytometry analysis of CD8+
T cells in Fig. 5b gave the similar results to that of CD4+
T cells. The production of CD8+ T cell subsets were also
significantly higher in mice immunized with HBc than
those immunized with PBS (p < 0.05). The production of
CD8+ T cells elicited by CpG-Au@HBc VLPs (13.4 %)
revealed higher level than those induced by CpG@HBc
VLPs (11.7 %; p < 0.05) and CFA/IFA +HBc VLPs
(9.47 %; p < 0.05). Hence, CpG-Au@HBc VLPs had great
potential as immunostimulatory vaccine formulation for
the generation of specific T cell responses than CpG@HBc
Fig. 4 HBc-specific IgG antibody titers (reciprocal serum dilution)
induced by HBc VLPs, CpG@HBc VLPs, CpG-Au@HBc VLPs, CpG-Au +HBc
VLPs, CFA/IFA +HBc VLPs, and PBS in BALB/C mice, respectively. Mice
(n= 6) were intraperitoneally vaccinated on days 0, 7, 14, and 21 as
described in the “Methods” section and detected antibody titers at the
end of each week. The results represent anti-HBc titers as the means
from six mice ± standard deviation (SD). The statistical significance of the
results was analyzed (PBS group served as control, all the other groups
contrasted with PBS group) and indicated: *p< 0.05; **p< 0.01
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VLPs and CFA/IFA +HBc VLPs. Besides, Au NPs made
the vaccine formulation much more efficient to induce
immune response.
IFN-γ, IL-2, and IL-4 Cytokine ELISA
It is well known that cytokines IFN-γ can induce Th1 dif-
ferentiation and IL-4 can induce Th2 differentiation. An-
other cytokines IL-2 can induce both Th1/2 differentiation
[35]. The secretions of these cytokines were evaluated to
study the effects of CpG-Au@HBc VLPs on both humoral
and cellular immune responses. As shown in Fig. 6,
immunization with CFA/IFA +HBc VLPs resulted in Th2-
dominated immune responses characterized by HBc-
specific secretion of IL-4 but not IFN-γ and IL-2. In
contrast, immunization with CpG ODNs (CpG@HBc
VLPs, CpG-Au +HBc VLPs, and CpG-Au@HBc VLPs
Fig. 5 Induction of HBc-specific CD4+ and CD8+ T cells after immune with HBc VLPs, CpG@HBc VLPs, CpG-Au@HBc VLPs, CpG-Au + HBc VLPs,
CFA/IFA + HBc VLPs, and PBS, respectively. The splenocyte surface molecules expressions were determined with flow cytometry analysis. A
representative result of three independent experiments was shown in (a); the data shown in (b) and (c) were determined as means ± SD from
three experiments. The statistical significance of the results was analyzed and indicated: *p < 0.05. ns no significant difference
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groups) generated high levels of HBc-specific IFN-γ and
IL-2 secretion and decreased HBc-specific IL-4 produc-
tion. The result was in accordance with the previous study
that CpG ODNs could switch the immune response to a
Th1-dominated cytokine pattern [16]. The production of
IL-4 triggered by CpG-Au@HBc VLPs was more than that
triggered by CpG@HBc VLPs (p < 0.05), but is consider-
ably less than that triggered by CFA/IFA + HBc VLPs
(p < 0.01), and showed no significant difference with CpG-
Au +HBc VLPs. This result was consistent with the result
of anti-HBc titer in Fig. 4, demonstrated that CpG-
Au@HBc VLPs could induce Th2 cell immune response to
activate higher humoral immune response than CpG@HBc
VLPs. On the other hand, the secretion of IFN-γ was sig-
nificantly higher in BALB/c mice immunized with CpG-
Au@HBc VLPs than other groups (p < 0.05). However, the
secretion of cytokine IL-2 presented no significant differ-
ence (p > 0.05) among CpG@HBc VLPs, CpG-Au +HBc
VLPs, CpG-Au@HBc VLPs, and CFA/IFA +HBc VLPs. It
was thus indicated that strong Th1 cell immune response
was also stimulated by CpG-Au@HBc VLPs.
In general, the above results suggested that CpG-
Au@HBc VLPs could induce stronger cellular immune
response when compared with CpG@HBc VLPs and
CFA/IFA +HBc VLPs, respectively. Meanwhile, this
nanocomposite could also stimulate greater humoral im-
mune response when contrast with CpG@HBc VLPs.
Such robust immune responses caused by low dosage of
adjuvant (CpG ODNs) could help to reduce the side ef-
fects in mice. Besides, Au NPs of this nanocomposite
played an important role in inducing both Th1- and
Th2-dominated response.
Conclusions
In summary, a highly monodisperse and uniform CpG-
Au@HBc VLPs nanocomposite was developed through a
dissociation and reassembling process. The obtained
adjuvant-containing VLPs exhibited both strong humoral
and cellular immune stimulation ability. Noteworthy, Au
NPs, which were conjugated with CpG ODNs, could
enhance the immunogenicity of the nanocomposite
through helping to stimulate both Th1- and Th2-
dominated immune response. This new type of immu-
nostimulatory nanocomposites is thus expected to be as
a potential vaccine for prophylactic and therapeutic ap-
plication, even for tumor immunotherapy.
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